TipRanks
Advertisement
Advertisement

DE:IDDA Stock Latest News

Innate Pharma says previously announced partnership with Sobi now effective
The FlyInnate Pharma says previously announced partnership with Sobi now effective
1d ago
IPHA
Innate Pharma price target raised to $9 from $8 at BTIG
PremiumThe Fly
Innate Pharma price target raised to $9 from $8 at BTIG
1M ago
IPHA
Leerink upgrades Innate Pharma to Outperform after lacutamab deal
PremiumThe Fly
Leerink upgrades Innate Pharma to Outperform after lacutamab deal
1M ago
IPHA
Innate Pharma upgraded to Outperform from Market Perform at Leerink
PremiumThe Fly
Innate Pharma upgraded to Outperform from Market Perform at Leerink
1M ago
IPHA
Innate Pharma price target raised to $7 from $5 at H.C. Wainwright
PremiumThe Fly
Innate Pharma price target raised to $7 from $5 at H.C. Wainwright
1M ago
IPHA
Innate Pharma, Sobi to enable initiation of the TELLOMAK-3 study
PremiumThe FlyInnate Pharma, Sobi to enable initiation of the TELLOMAK-3 study
1M ago
IPHA
Innate Pharma CMO Sonia Quaratino to depart, Markus Jensen to succeed
Premium
The Fly
Innate Pharma CMO Sonia Quaratino to depart, Markus Jensen to succeed
1M ago
IPHA
Innate Pharma completes enrollment in dose escalation of IPH4502 study
Premium
The Fly
Innate Pharma completes enrollment in dose escalation of IPH4502 study
2M ago
IPHA
Innate Pharma: Buy Rating Reaffirmed on Pipeline Momentum and De‑Risking Catalysts; $8 Price Target Unchanged
PremiumRatings
Innate Pharma: Buy Rating Reaffirmed on Pipeline Momentum and De‑Risking Catalysts; $8 Price Target Unchanged
4M ago
IPHA
Innate Pharma: Underappreciated Topo‑I ADC Pipeline and Differentiated IPH4502 Support Buy Rating
PremiumRatings
Innate Pharma: Underappreciated Topo‑I ADC Pipeline and Differentiated IPH4502 Support Buy Rating
5M ago
IPHA
Innate Pharma assumed with a Buy at BTIG
PremiumThe Fly
Innate Pharma assumed with a Buy at BTIG
6M ago
IPHA
Innate Pharma: Diversified Oncology Pipeline and AstraZeneca Partnership Create Compelling Upside Ahead of 2026 Inflection Points
PremiumRatings
Innate Pharma: Diversified Oncology Pipeline and AstraZeneca Partnership Create Compelling Upside Ahead of 2026 Inflection Points
6M ago
IPHA
Innate Pharma announces FDA clearance to proceed with TELLOMAK 3 trial
PremiumThe FlyInnate Pharma announces FDA clearance to proceed with TELLOMAK 3 trial
10M ago
IPHA
Innate Pharma upgraded to Buy from Neutral at H.C. Wainwright
Premium
The Fly
Innate Pharma upgraded to Buy from Neutral at H.C. Wainwright
11M ago
IPHA
Innate Pharma initiated with a Buy at Lucid Capital
Premium
The Fly
Innate Pharma initiated with a Buy at Lucid Capital
11M ago
IPHA
Innate Pharma management to meet with BTIG
PremiumThe Fly
Innate Pharma management to meet with BTIG
12M ago
IPHA
Innate Pharma management to meet with BTIG
PremiumThe Fly
Innate Pharma management to meet with BTIG
12M ago
IPHA
Target initiated, Nike upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Target initiated, Nike upgraded: Wall Street’s top analyst calls
12M ago
DG
HD
Innate Pharma downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Innate Pharma downgraded to Neutral from Buy at H.C. Wainwright
12M ago
IPHA
Innate Pharma SA Reports First Half 2025 Financial Results
PremiumCompany AnnouncementsInnate Pharma SA Reports First Half 2025 Financial Results
1y ago
IPHA
Innate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating
Premium
Ratings
Innate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating
1y ago
IPHA
Innate Pharma downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
Innate Pharma downgraded to Market Perform from Outperform at Leerink
1y ago
IPHA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >